QT Imaging's Shipment-and-Guidance Print Is a Contained Long - But It Is PR-Heavy
The Opportunity
This is a contained, single-artefact micro-cap signal: the company reports a material revenue and shipment ramp and offers a forward guide that, if real, is the kind of "commercialisation inflection" micro-caps trade on. The directional call is LONG on QTI with 47% conviction: the thesis is that reported revenue ($18.9m for 2025) and shipment cadence (40 scanners in 2025, 17 in Q4) plus 2026 guidance (~$39m) create a positive revision and attention setup before broader institutional coverage forms.
The Timing
The tape is Bearish 78 with crosswind risk 66 and this is a LONG with Headwind 34, so execution risk is not trivial. Freshness is 72, but staleness is flagged as possible_reprint because the artefact is a syndicated press-release host. In other words: the numbers are crisp, but the propagation path is PR-driven, so the timing edge is about whether the market treats the print as credible and durable rather than about discovering hidden information.
The Evidence
The primary source provided is pharmiweb.com , observed 25 March 2026. Upstream due diligence explicitly warns that this appears to be a mirrored/hosted press release, not independent reporting, and 7.1 validation finds retail-only discussion with no institutional/practitioner confirmation. Price context is factual only: QTI is $6.90 (+5.0%) on the latest trading day.